公司年报点评：2024，进入微芯原创新药收获之年

[Table_Summary] 投资要点： ● 公司已在尿路上皮摇、非小细胞肺癌等适应症上已经看到了很不错的数据。公司预计 2024 年可以看到西达本胺联合 PD-1 一线治疗非小细胞肺癌的随机、双盲、多中心 II 期结果。 请务必阅读正文之后的信息披露和法律声明 In 2024, multiple data readouts and submissions for market approval are expected. Data for Xidabenamine in diffuse large B-cell, Siglitin in NASH phase II, Xidabenamine + PD-1 in first-line non-small cell lung cancer phase II, and Theoroni in small cell lung cancer phase III are anticipated, with Theoroni expected to apply for market approval. | --- | --- | --- | --- | |------ ...